11:21 AM EST - BELLUS Health Inc. : Announced that the U.S. Patent and Trademark Office has issued U.S Patent No. 10,111,883, granting claims for the use of BELLUS Health's lead drug candidate BLU-5937 for the treatment of chronic cough without affecting taste response. BELLUS Health Inc.
shares T.BLU are trading up $0.02 at $0.79.
